Skip to main content
eScholarship
Open Access Publications from the University of California

School of Medicine

Independent Study Projects bannerUC San Diego

Platelet rich plasma for the treatment of foot and ankle pathologies

Abstract

Platelet rich plasma (PRP) is a concentrate of platelets and their bioactive factors derived from the peripheral venous blood of patients. Platelets contain factors that improve healing and tissue regeneration. PRP may offer an excellent means of non-operatively treating foot and ankle pathology. Objectives: to determine whether PRP injections improve outcomes for foot and ankle pathologies. Methods: A retrospective cohort study of patients aged ≥ 18 years diagnosed with foot or ankle pathology at University of California San Diego between January 2011 and September 2016 was performed. Patients treated with an intra-articular injection using platelet-rich plasma were categorized into the PRP group. Age and gender matching were used to select active comparator group (triamcinolone injection), and a control group (conservative treatment). Primary outcomes were patient-reported pain and function before treatment and at 12 weeks post-treatment. Pain ranged from 1-10 with higher scores corresponding to higher perception of pain. Function was determined by patient-reported activity limitations and scored according to the Amerian Orthopedic Society Foot and Society (AOFAS) ankle hindfoot scale. High scores corresponded to better function. Results: we identified four patients that met inclusion criteria for the PRP group (n=4), with age and gender matching for tiramcinolone (n=4), and control (n=4). Patients averaged 41 years old, (range 26-61), were 75% female, and had an average BMI of 28.9 (range 19.7-44.3). The median pain score before and after treatment did not change significantly after 12 weeks in the PRP group (95% CI-1,8; P=0.19), triamcinolone group (95% CI-7,5; P=.88), or the control group (95% CI-1,7; P=.08). Functional scores before and after treatment did no significantly change after 12 weeks in the PRP group (95% CI-3,0; P=.058), triamcinolone group (95% CI-6,3; P=.74), or the control group (95% CI-6,6; P=1). There was no significant difference in change of pain or change of function between PRP, triamcinolone, and conservative therapy (P=.31, P=.09, respectively). Conclusion: among patients with foot ankle pathologies at UCSD, PRP did not result in greater improvement in pain or function at 12 weeks post-treatment compared to triamcinolone or conservative treatment.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View